

OHDSI in Korea

Rae Woong Park, MD, PhD

Department of Biomedical Informatics,
Ajou University, School of Medicine,
Korea

Contents

- Korean OHDSI Network
- Why DRN and CDM is popular to Korea?
- Lesson learned from potential Data Owner
- Future plans in Korean OHDSI

Korean OHDSI network: 18



CDM Conversion Status

- Conversion completed: 4 institutions
 - Ajou University Hospital: 2.3M, 23 years EHR
 - Gachun Gil University Hospital: 2M, 10 years EHR
 - Kangwon National University Hospital: 0.5M, 10 years EHR
 - NHIS: 2M, 12 years, Claim + regular health exam (2018: 51M, 12 years)
- Conversion in progress 14 institutions
 - **By the end of 2017: 2**
 - Samsung Medical Center
 - Wonkwang University Hospital
 - Wonju Severance Hospital
 - **By the end of 2018: 14**
 - Chonbuk National University Hospital
 - Yonsei University Severance Hospital
 - Korea University Anam Hospital
 - Korea University Guro Hospital
 - Korea University Ansan Hospital
 - Gangdong Sacred Heart Hospital
 - Hanyang University Hospital
 - Ehwa University Mokdong Hospital
 - Ehwa University Magok Hospital
 - Cha University Hospital
 - HIRA/NHIS (51M, 12 years)

<MOU>



Activity in Korea

■ Leadership meeting

- Bimonthly
- Leaders in charge of CDM for each hospital
- Important decisions and policy-related issues



■ Engineer meeting

- Biweekly, TC (current 9th)
- EHR experts from participating hospitals
- Discuss all the technical issues during CDM conversion

Activity in Korea

■ Open forum

- Monthly, 3 hour lecture
- Agenda
 - Introduction to OHDSI and CDM
 - OMOP CDM Structure
 - OMOP CDM Vocabulary/ vocabulary mapping
 - Tools for OMOP CDM
 - ETL process
 - Research Experience using OHDSI Network



CDM conversion Standard Operation Procedure (SOP)

| | Step | Time-line | Human Resources From Data Partner | Role of Data Partner | Role of Supporting Organization | Contact |
|---|------------------------|--|--|---|---|---------------------------------------|
| 1 | MOU | | CDM director and engineer | Administrative affair | Administrative affair | shinda@ajou.ac.kr |
| 2 | Advance Preparation | - | CDM director and engineer | Budget for H/W, S/W, human resources | Orientation, lecture and consultation | |
| 3 | Vocabulary Extraction | 1 wk | EMR expert | Frequency table of every drug, supply, procedure, diagnosis, lab test | Support | |
| 4 | Vocabulary Mapping | - Vocabulary customization: 2 mon - Code mapping: 3 mon | Medical expert x 2 (physician x1, Nurse x 1) | Support | Code mapping between local code and OMOP vocabulary (voca covering 99% of data) | hidoyebi@ajou.ac.kr |
| 5 | ETL Definition | 2 mon | EMR expert x1 Medical expert x 1 | ETL document | Support | enzo@ajou.ac.kr bacojun@ajou.ac.kr |
| 6 | ETL | 2 - 4 weeks | DB expert x 1 | ETL Query | Support | |
| 7 | OHDSI Tool application | 1 - 4 weeks | R/JAVA expert x 1 | Achilles, Atlas, etc installation | Support | jsh90612@gmail.com |
| 8 | DQM | 4 -8 weeks | DB expert Medical expert | Run DQM codes | Provide DQM codes and evaluation and feedback | enzo@ajou.ac.kr bacojun@ajou.ac.kr |

1) SOP for MOU

| 1. 협의사항 | |
|---------------------------------|---|
| 단계 | 방법 |
| MOU | 1단계 신대에 담당자를 통해 MOU 협약 내용 알림 * 전화번호 : 031-219-4473 * e-mail : shinda@ajou.ac.kr |
| | 2단계 아주대병원 연구지원팀 이해경 선생님께 연결하여 협약 진행 * 전화번호 : 031-219-4414 * e-mail : seah0001@ajou.ac.kr |
| 단계 | 방법 |
| 용 이 매 평 계 약 서 | 1단계 신대해당담당자를 통해 용이매평사용제약서 가연파일을 전달 받기 |
| | 2단계 참여기관에서 제약서 내용 파악 및 수정후, 신대해당담당자에게 전달 |
| | 3단계 제약서 수정이 완료되면 아주대병원 연구지원팀 이해경 선생님께 전달하여 제약 진행 |
| 협의사항 | 비고 |
| 1 학습 시간 | 연한 작업 학습일정 계획 |
| 2 작업 기간 | 실제 예상 작업 기간 협의 |
| 3 연한 소스 DB | EMR에서 직접 데이터를 추출할 것인지, 별도로 구축된 DW에서 데이터를 추출할 것인지 협의 |
| 4 소스 데이터 추출 형태 | DUMP 파일 형태로 추출 권장 |
| 5 CDM 구축 범위 | 연한 대상 CDM 데이터분, 전체 데이터분 혹은 CDM 데이터분들을 단계별로 구축계획 연한 대상 데이터의 기간 범위(예: 2010년 ~ 2015년) |
| 6 CDM 업데이트 정책 | 1) 업데이트 주기 2) 버전 관리 방법 - 신규 DB 생성 혹은 기존 데이터분에 추가 |
| 7 운용 장비/설비 | 참여기관 환경검토 예) DBMS 종류, 원격지원 가능여부, 보안정책, 라이선스 등 |
| 8 참여 인력 및 지원 인력 | 전담 인력, 서포트 인력의 수와 역할 전담 인력이 갖추어야 할 필수 자격/능력 요건 |
| 9 데이터/적용도구 공개 수준 | Achilles 등의 tool 적용 후 공개수준(원내/원외/비공개) |
| 10 인력 지원 방식 | 지원인력: 상주, 방문, 원격 |
| 11 인력 교육 | 시기, 횟수 및 방법(강문, 원격) |
| 12 협의 일정 | 협의 주기, 협의 방법, 참석자 |

2) SOP for Advance Preparation

| | 구분 | Spec | 규격 | 비고 |
|---|-------------------|-----------------------------|--|--|
| 1 | Model | DELL POWEREDGE R730XD | 2U rack server | ETL수행 및 분석용 서버 1대 구성 |
| 2 | Processors | INTEL XEON E5-2667V4 3.2GHZ | CPU * 2EA (8Core, 16Thread) | 최소요구사항 |
| 3 | Memory | 768 GB, 24 x 32GB | PC4-17000P DDR4-2133 REGISTERED ECC MEMORY | 320 GB 이상 추천 |
| 4 | Hard Drive | 18 X DELL 1.6TB | MLC SAS III SSD 2.5 INCH ENTERPRISE CLASS | 4TB 이상 추천 (자체산정, CDM 및 원본 데이터 용량 고려) 빠른 연산 속도를 원하는 경우 intel SSD 1.2TB PCIE 추천 |
| 5 | Raid Controller | PERC H730 1GB CACHE | 12GB/S RAID CONTROLLER | 최소요구사항 |
| 6 | Management | IDRAC8 ENTERPRISE | Web base | 웹 기반의 원격 서버 관리툴 |
| 7 | Networking option | 1GBE Network card | *4 | 고속 네트워킹 선택사항 |
| 8 | Power Supply | Dual 1100W | - | 최소요구사항 |

2.Server - Web

| | 구분 | Spec | 규격 | 비고 |
|---|-------------------|--------------------------------------|----------------------------------|--|
| 1 | Model | HP ProLiant Server DL 380 Gen9 | 2U rack server | 1개의 베어본 서버 Web 서버용 |
| 2 | Processors | Intel Xeon E5-2640v3 (2.6GHz) | CPU *1EA (8Core, 16Thread) | - |
| 3 | Memory | 16 GB (Max 768GB) | DDR4-2133R REGISTERED ECC MEMORY | ATLAS 운영을 위한 최소 요구 사항 256GB 이상 |
| 4 | Hard Drive | NONE | Hot Plug 8 Bay | System OS 구성을 위한 SSD 512 GB 저장공간 할당을 위한 SAS HDD 1TB * 7EA |
| 5 | Raid Controller | SATA drives and supports Raid 0,1,10 | Smart Array P440ar/2GB | HDD Raid용 컨트롤러 |
| 7 | Networking option | 4*1Gb Ethernet | 331i Adapter | - |
| 8 | Power Supply | 1 * 500W Flex Slot (94%+) | 2U Rack from factor | - |

3. Software

| | 구분 | Spec | 규격 | 비고 |
|---|------------------|----------------------------|--------------------|--------------|
| 1 | OS | Window server 2012 | Enterprise license | 권장사항 |
| 2 | DB | SQL Server 2012 | Standard or more | 권장사항 |
| 3 | Web service tool | Apache Tomcat 7 | Free license | 필수 |
| 4 | Env. | Java Development Kit (JDK) | Over 7 version | - |
| 5 | Base application | R | Over 3.3 version | - |
| 6 | Base application | R studio | Lastest version | - |
| 7 | Base application | R tools | Lastest version | OS와 호환 여부 확인 |

4. License (연간계약)

| | 구분 | 요구사항 |
|---|----|---|
| 1 | 용어 | SNOMED CT |
| 2 | 용어 | medical terms for insurance to OMOP concept ID mapping table) |
| | | |
| | | |

*비용은 라이선스 구매관련하여 아래와 같습니다.

- MS Window server standard (교육용) : 약 70 만원
- MS SQL standard 2016(교육용) : 약 130만원
- 용어매핑 저작권 사용 비용 : 1000만원 (연간 계약필요, 참여기관이 증가할수록 비용이 늘어날 예정)
- SNOMED 라이선스 : 약 200만원 (연간 계약필요)

3) SOP for Vocabulary Extraction

(1) 공통사항

- 각 테이블의 필드에서 '~ concept_id'로 표기된 필드에는 OMOP에서 제공하는 concept 테이블 내의 concept_id가 들어가야 함

- concept 테이블 내의 필드정보 중 다음의 조건을 만족하여야 함

| 필드명 | 조건 |
|------------------|--|
| concept_name | 유사수준이 가장 높은 concept_id를 찾아야 함 |
| domain_id | 각 OMOP CDM 테이블에 맞아야 함 (ex: drug_exposure 테이블의 drug_concept_id에 들어갈 concept_id의 domain_id는 'Drug') |
| standard_concept | S |
| invalid_reason | NULL 또는 공백 |
| | |

(2) 매핑과정

| 순번 | 항목 | 설명 |
|----|-----------------|---|
| 1 | Vocabulary 다운로드 | 데이터 신청양식을 채우고, 필요한 용어의 체크박스에 체크한 뒤 신청하면, 수 분 뒤 이메일을 통해 받은 링크에서 다운로드가 가능함 (http://athena.ohdsi.org/) |
| 2 | 분리된 용어 통합 | CPT4와 같이 EULA가 요구되는 용어를 체크하여 다운받은 경우 다운받은 파일 중 포함된 안내에 따라 vocabulary 파일에 통합함 (EULA는 athena 사이트 링크를 통해 설명을 숙지해야 함) |
| 3 | USAGI 설치 | 다음의 링크에서 파일을 다운받고 안내에 따라 설치함 (https://github.com/OHDSI/Usagi) |
| 4 | USAGI와 용어파일 통합 | USAGI의 파일메뉴에서 vocabulary 파일들이 있는 위치를 지정 |
| 5 | 소스파일 정리 | 매핑하고자 하는 용어의 정보를 csv 파일로 정리함 (필수: 소스코드, 소스코드 영문설명; 추가: 추가설명 또는 빈도 등) |
| 6 | 임시 매핑 | USAGI에서 소스파일을 로드하여, 설명에 따라 sourcecode, description 및 additional info가 저장된 컬럼을 지정하고, 매핑조건(domain, vocabulary 등)을 지정하여 단어유사성 기반의 임시 매핑을 실행 (용량에 따라 수분에서 수십분이 소요될 수 있음) |
| 7 | 본 매핑 | 임시매핑된 결과를 하나씩 확인하면서, 검색을 통해 새로운 concept_id로 수정하고, 매핑완료된 단어쌍에 대해 confirm하여 진행 |
| 8 | 교차비교 | 각 매핑은 2인에 의해 각각 이루어지며, 매핑결과를 비교하여 두사람이 다르게 매핑한 경우에 대해 논의하여 합의를 도출 |
| 9 | 3자검토 | 합의가 도출되지 못한 경우, 또는 추가 논의가 필요한 경우에 대하여 제 3자가 재검토를 통해 최종 매핑결과 도출 |

5) SOP for ETL documentation

The image displays a 4x4 grid of 16 screenshots, each showing a different page or section of an ETL documentation template. The templates are organized into four main sections, each with a yellow header. The sections are:

- Section 1 (Top Left):** Focuses on the overall ETL process, including data source information, target table details, and a summary of the transformation logic.
- Section 2 (Top Right):** Details the data flow, showing the sequence of tables and the transformations applied between them.
- Section 3 (Bottom Left):** Provides a detailed view of the transformation logic, including the specific SQL or code used for each step.
- Section 4 (Bottom Right):** Contains a detailed description of the data, including the source and target tables, the data types, and the specific transformations applied.

Each screenshot shows a table with columns for the following information:

- Table Name:** The name of the table being processed.
- Source:** The source of the data, such as a database or file.
- Target:** The target table or destination.
- Transformation:** The specific logic or code used to transform the data.
- Comments:** Additional notes or explanations for the transformation.

GOVERNMENT'S INTEREST ON CDM

Minister of Mistry of Trade, Industry and Energy of South Korea formally announced that they launch a TF team for distributed bio-dig data sharing to build a national biomedical data sharing platform and environment. This year, they will make a master plan for it and prepare budget to realize it.

≡
dongA.com
f t q

신문보기 | 보이스뉴스

뉴스
 오피니언
 연예
 스포츠
 스튜디오
 비즈N

ENG | 中文 | 日文

Apr 18, 2017

< 경제

병원 의료데이터 분석치, 제약사 등에 제공 길 열린다

박민우기자 입력 2017-04-18 03:00 수정 2017-04-18 03:00

🔊
📄
가
가

0

f

t

🗨️

⋮

**정부, 맞춤형 의료서비스 제공위해 민관 바이오 빅데이터 구축하기로
개인정보法 따라 원본은 제공 안해**

분산형 바이오 빅데이터 모델

```

    graph LR
      H[병원] -- "분석SW" --> B[바이오 빅데이터 센터]
      B -- "분석결과" --> H
      C[수요 기업] -- "분석의뢰" --> B
      B -- "분석결과" --> C
      I[IT기업] -- "분석SW발주" --> B
      B -- "분석SW납품" --> I
      subgraph Source [자료: 산업통상자원부]
        I
      end
      style Source fill:none,stroke:none
    
```

주요뉴스

1/3 < >

“시진핑 부패 폭로” 자산19조 재벌, 당국과 ...

文 37.5%, 安 26.4%...격차 두자
릿수로 벌어져

美 핵잠수함 미시간호, 25일 부산항 온다...北
에 대한 강력한 경고?

美, 北 선제타격 못하는 이유가 한국 수도권 2
500만 인구 때문이라고?

바른정당 긴급의총 돌입...유승민 후보 사퇴
여부 논의

장시호 “특검서 만난 崔, 삼성동 사저 돈 빼내
정유라 키우라고 해” 주장

칩거 깐 김한길 “문재인,盧비서실장이라 지
도자 추대...난센스”


김진태 “妄, 변성기 중1 같아...더듬거리는 거
보면 때려죽고파”

#

정부가 4차 산업혁명 시대에 걸맞은 맞춤형 의료 서비스를 제공하기 위해 바이오 빅 데이터 시스템을 만드는 작업에 착수한다.

산업통상자원부는 17일 경기 성남시 판교 메리어트호텔에서 ‘바이오헬스 업계 간담 회’를 열고 이 같은 내용을 포함하는 바이오헬스 산업 발전전략을 발표했다.

Distributed Bio Big Data Model




NHIS*, Development of a CDM-based Drug Safety Surveillance System

Three year project 2016-2018

- 1st year: feasibility
12 year of 1M pt data into CDM
- 2nd year; validation of usefulness of the CDM
- 3rd year : Full conversion
12-years of 51 M patients

Claim data,
NHIS



Collaboration and competition in between government

■ Ministry of Trade, Industry and Energy

DRN, OMOP-CDM
EMR + Omics + life-log

■ Ministry of Health and Welfare

merge, HL7 CDA?
OMOP-CDM?
EMR + Claim

■ National Health Insurance Service

DRN, OMOP-CDM
Claim + Health Exam

■ Ministry of Food And Drug Safety

DRN, K-CDM (?)
EMR

■ Ministry of Science, ICT and future planning

HIS with CDM

Characteristics of Korean OHDSI


Korean OHDSI

■ Data partners:

- Major tertiary teaching hospitals
 - Detailed time stamp
 - Test results
 - Outcome data

■ National Health Insurance Data

- Compulsory health insurance
- Claim data + socioeconomic data + regular Health exam data (includes lab tests)
- 12-year of observation period
- Covers all the citizens (51M)




WHY DRN AND CDM IS POPULAR TO KOREA?



Invited Talks

- 157 invited talks during past 33 months since July 2014.
 - 2014: 13 times
 - 2015: 42 times
 - 2016: 74 times
 - 2017: 28 times

No. of Presentations and Data Partner Join



**Lesson
learned from
potential
Data Owner**


- Quick-prototyping
- Live demonstration
- Success story
- Focusing on clinicians

**Lesson
learned from
potential
Data Owner**

- Quick-prototyping
 - Launch Achilles ASAP!
 - Need vocabulary mapping!

Code Mapping

>170K codes to map




- EDI (Electronic Data Interchange) code in Korea
 - National standard for national health insurance claim
 - Managed by Health Insurance Review & Assessment Service (HIRA)

Strategy for Standard Vocabulary Mapping

- Sort codes by frequency of usage
- Number of codes required to cover

95 % of transaction data → 99% → 100%
20-30% of codes 60-70% of codes




No. of drug codes (Ajou Univ.)₂₅

DRUG code mapping (Ajou Univ.)

Source code: local code of Ajou university hospital (mapped with EDI, partially)

Standard code: RxNorm, ATC



**Lesson
learned from
potential
Data Owner**

- **Live demonstration** using
RWD

Achilles: data characterization

Openness: <http://ami.ajou.ac.kr:8080>



Malignant tumor, Breast


Ajou Univ. Hospital 2.3M 22years

| SOC | | | Person Count | Prevalence | Records per Person |
|-----|----|---|--------------|------------|--------------------|
| NA | NA | Benign tumor of breast | 27,261 | 1.20% | 3.61 |
| NA | NA | Primary malignant neoplasm of breast | 5,920 | 0.26% | 28.90 |
| NA | NA | Fibrocystic disease of breast | 2,968 | 0.13% | 2.76 |
| NA | NA | Breast finding | 1,671 | 0.07% | 2.76 |
| NA | NA | Primary malignant neoplasm of breast upper outer quadrant | 1,539 | 0.07% | 5.44 |


Showing 1 to 5 of 34 entries (filtered from 5,156 total entries)

Primary malignant neoplasm of breast


Condition Prevalence




Condition Prevalence by Month



Conditions by Type



Age at First Diagnosis



Malignant tumor, Breast


NHISS, 1M sample cohort, 10 years

| SOC | | | Person Count | Prevalence | Records per Person |
|-----|----|--------------------------------------|--------------|------------|--------------------|
| NA | NA | Inflammatory disorder of breast | 11,296 | 1.00% | 2.03 |
| NA | NA | Fibrocystic disease of breast | 7,569 | 0.67% | 2.06 |
| NA | NA | Fibroadenosis of breast | 7,164 | 0.64% | 1.65 |
| NA | NA | Primary malignant neoplasm of breast | 4,701 | 0.42% | 29.01 |
| NA | NA | Solitary cyst of breast | 3,405 | 0.30% | 1.49 |


Showing 6 to 10 of 39 entries (filtered from 5,989 total entries)

Primary malignant neoplasm of breast


Condition Prevalence




Condition Prevalence by Month



Conditions by Type



Age at First Diagnosis



**Lesson
learned from
potential
Data Owner**

- Using a **Success story** and role model

Examples of clinical researches using big data



COLLOQUIUM
PAPER

Characterizing treatment pathways at scale using the OHDSI network

George Hripcsak^{a,b,c,1}, Patrick B. Ryan^{c,d}, Jon D. Duke^{c,e}, Nigam H. Shah^{c,f}, Rae Woong Park^{c,g}, Vojtech Huser^{c,h}, Marc A. Suchard^{c,i,j,k}, Martijn J. Schuemie^{c,d}, Frank J. DeFalco^{c,d}, Adler Perotte^{a,c}, Juan M. Banda^{c,f}, Christian G. Reich^{c,l}, Lisa M. Schilling^{c,m}, Michael E. Matheny^{c,n,o}, Daniella Meeker^{c,p,q}, Nicole Pratt^{c,r}, and David Madigan^{c,s}

^aDepartment of Biomedical Informatics, Columbia University Medical Center, New York, NY 10032; ^bMedical Informatics Services, NewYork-Presbyterian Hospital, New York, NY 10032; ^cObservational Health Data Sciences and Informatics, New York, NY 10032; ^dEpidemiology Analytics, Janssen Research and Development, Titusville, NJ 08560; ^eCenter for Biomedical Informatics, Regenstrief Institute, Indianapolis, IN 46205; ^fCenter for Biomedical Informatics Research, Stanford University, CA 94305; ^gDepartment of Biomedical Informatics, Ajou University School of Medicine, Suwon, South Korea, 443-380; ^hLister Hill National Center for Biomedical Communications (National Library of Medicine), National Institutes of Health, Bethesda, MD 20894; ⁱDepartment of Biomathematics, University of California, Los Angeles, CA 90095; ^jDepartment of Biostatistics, University of California, Los Angeles, CA 90095; ^kDepartment of Human Genetics, University of California, Los Angeles, CA 90095; ^lReal World Evidence Solutions, IMS Health, Burlington, MA 01809; ^mDepartment of Medicine, University of Colorado School of Medicine, Aurora, CO 80045; ⁿDepartment of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN 37212; ^oGeriatric Research, Education and Clinical Center, VA Tennessee Valley Healthcare System, Nashville, TN 37212; ^pDepartment of Preventive Medicine, University of Southern California, Los Angeles, CA 90089; ^qDepartment of Pediatrics, University of Southern California, Los Angeles, CA 90089; ^rDivision of Health Sciences, University of South Australia, Adelaide, SA, Australia 5001; and ^sDepartment of Statistics, Columbia University, New York, NY 10027

Edited by Richard M. Shiffrin, Indiana University, Bloomington, IN, and approved April 5, 2016 (received for review June 14, 2015)

Observational research promises to complement experimental research by providing large, diverse populations that would be infeasible for an experiment. Observational research can test its own clinical hypotheses, and observational studies also can contribute to the design of experiments and inform the generalizability of experimental research. Understanding the diversity of populations and the variance in care is one component. In this study, the Observational Health Data Sciences and Informatics (OHDSI) collaboration created an international data network with 11 data sources from four countries, including electronic health records and admin-

Without sufficiently broad databases available in the first stage, randomized trials are designed without explicit knowledge of actual disease status and treatment practice. Literature reviews are restricted to the population choices of previous investigations, and pilot studies usually are limited in scope. By exploiting the ClinicalTrials.gov national trial registry (9) and electronic health records, researchers already have demonstrated the discrepancy between targeted populations and populations available for study (10), raising the concern that designs may not be optimal. Designs cannot be based simply on current treatment recom-

**250M patients
12 database
5 countries**

MEDICAL SCIENCES


**Lesson
learned from
potential
Data Owner**

- Focusing on Clinicians

Focusing on clinicians

- Clinicians, rather than informaticians: major decision makers in a hospital are usually clinicians.
- Young clinicians (assistant – associate professors) : highest interest on OMOP CDM, because they do not have enough fund, resources and data for their research.
- Inter-disciplinary clinical meeting
 - then homogenous clinical meeting at initial stage

Invited Talks by domain



**HOW ABOUT PROVIDE FUND OR
INCENTIVES TO HOSPITAL?**

Not successful

Challenges and plans in Korean OHDSI

■ Expanding the data partners

- All the tertiary teaching hospitals
- Most of general hospitals
- Some of private clinics
- Most of pharmacies
- All the claim data covering all the Korean population

■ Governance for data sharing

- No IRB for pre-defined and verified analyses
- Open all the Achilles website of Korean data partner to public
- Maintain regular leadership meeting

■ Free sample data

- For training
- To test analytic code
- For Feasibility test

■ Real-time CDM

- Up to date information
- Real-time eligibility screening
- CDSS

■ CDM-based PHR

■ Expansion of CDM model for

- bio-signal data
- Genomic data
- Image data

Summary

- About South Korea
- Korean OHDSI Network
- Why DRN and CDM is popular to Korea?
- Lesson learned from potential Data Owner
 - Quick-prototyping
 - Live demonstration
 - Success story
 - Focusing on clinicians
- Projects/Tools
- Future plans in Korean OHDSI

Acknowledgements

Dukyong Yoon, MD, PhD
Hyun Wook Han, MD, PhD
Song Vogue Ahn, MD, PhD
Soo Yeon Cho, MPH
DaHye Shin, BS
JungHyun Byun, BS
Hojun Park, BS
MinSeok Jeon, BE
Sungjae Jung, BE
Doyeop Kim, BE
Sanghyung Jin, MS
Tae Young Kim, BE
Seojeong Shin, MS
Jaehyeong Cho, BS
Lee hye jin, MBA
Eun Sung Kim BS
Jaehee Han, BN

So Young Eo, BN
Hyo Hung Kim, BN
Eugene Jeong, BS
Seungbin Oh, BPharm
Yourim Lee, BS
Seng Chan You, MD, MS
Haze Lee
Jang ho Lee, BE
Taehwan Kim, BE
A Rum Lee, BS
EunBi Kim, BS
Yeo Kyung Lee, BS
Seong-yun Oh
Hyukjun Cho, MS
EunKang Kim
Yun Yeon Ju
Yujung Kwon
Soojung Cho, MPH